Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Galectin-3 in pre-B acute lymphoblastic leukemia.

Literature DB >> 23760399

Galectin-3 in pre-B acute lymphoblastic leukemia.

F Fei¹, H Abdel-Azim, M Lim, A Arutyunyan, M von Itzstein, J Groffen, N Heisterkamp.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23760399 PMCID： PMC3926504 DOI： 10.1038/leu.2013.175

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

× No keyword cloud information.

15 in total

Review 1. Treatment of acute lymphoblastic leukemia.

Authors: Ching-Hon Pui; William E Evans
Journal: N Engl J Med Date: 2006-01-12 Impact factor: 91.245

2. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.

Authors: Mio Yamamoto-Sugitani; Junya Kuroda; Eishi Ashihara; Hisao Nagoshi; Tsutomu Kobayashi; Yosuke Matsumoto; Nana Sasaki; Yuji Shimura; Miki Kiyota; Ryuko Nakayama; Kenichi Akaji; Tomohiko Taki; Nobuhiko Uoshima; Yutaka Kobayashi; Shigeo Horiike; Taira Maekawa; Masafumi Taniwaki
Journal: Proc Natl Acad Sci U S A Date: 2011-10-10 Impact factor: 11.205

3. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest.

Authors: Tadashi Yoshii; Tomoharu Fukumori; Yuichiro Honjo; Hidenori Inohara; Hyeong-Reh Choi Kim; Avraham Raz
Journal: J Biol Chem Date: 2001-11-27 Impact factor: 5.157

4. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors: K Nguyen; M Devidas; S-C Cheng; M La; E A Raetz; W L Carroll; N J Winick; S P Hunger; P S Gaynon; M L Loh
Journal: Leukemia Date: 2008-09-25 Impact factor: 11.528

5. Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells.

Authors: B Zhang; J Groffen; N Heisterkamp
Journal: Leukemia Date: 2007-03-29 Impact factor: 11.528

6. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients.

Authors: Pierre Vereecken; Ahmad Awada; Stefan Suciu; Gilberto Castro; Renato Morandini; Anna Litynska; Danielle Lienard; Khaled Ezzedine; Ghanem Ghanem; Michel Heenen
Journal: Melanoma Res Date: 2009-10 Impact factor: 3.599

Review 7. Contribution of bone microenvironment to leukemogenesis and leukemia progression.

Authors: F Ayala; R Dewar; M Kieran; R Kalluri
Journal: Leukemia Date: 2009-09-03 Impact factor: 11.528

8. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.

Authors: Cihangir Duy; Christian Hurtz; Seyedmehdi Shojaee; Leandro Cerchietti; Huimin Geng; Srividya Swaminathan; Lars Klemm; Soo-mi Kweon; Rahul Nahar; Melanie Braig; Eugene Park; Yong-mi Kim; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; H Phillip Koeffler; J Jessica Yu; Nora Heisterkamp; Thomas G Graeber; Hong Wu; B Hilda Ye; Ari Melnick; Markus Müschen
Journal: Nature Date: 2011-05-19 Impact factor: 49.962

9. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia.

Authors: Niklas Feldhahn; Anna Arutyunyan; Sonia Stoddart; Bin Zhang; Sabine Schmidhuber; Sun-Ju Yi; Yong-Mi Kim; John Groffen; Nora Heisterkamp
Journal: Oncoimmunology Date: 2012-08-01 Impact factor: 8.110

Review 10. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors: Wendy Stock
Journal: Leuk Lymphoma Date: 2010-02

16 in total

Review 1. A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors: Daniela S Krause; David T Scadden
Journal: Haematologica Date: 2015-11 Impact factor: 9.941

2. Role of MSC-derived galectin 3 in the AML microenvironment.

Authors: Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff
Journal: Biochim Biophys Acta Mol Cell Res Date: 2018-04-12 Impact factor: 4.739

Review 3. Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness.

Authors: Camilo Pena; Leonardo Mirandola; Jose A Figueroa; Nattamol Hosiriluck; Natallia Suvorava; Kayley Trotter; Adair Reidy; Rahman Rakhshanda; Drew Payne; Marjorie Jenkins; Fabio Grizzi; Lauren Littlefield; Maurizio Chiriva-Internati; Everardo Cobos
Journal: Ann Transl Med Date: 2014-09

Review 4. Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors: Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal: Semin Oncol Date: 2017-07-11 Impact factor: 4.929

Review 5. The nuclear export protein XPO1 - from biology to targeted therapy.

Authors: Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal: Nat Rev Clin Oncol Date: 2020-11-10 Impact factor: 66.675

Review 6. The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia.

Authors: Erica Dander; Chiara Palmi; Giovanna D'Amico; Giovanni Cazzaniga
Journal: Int J Mol Sci Date: 2021-04-23 Impact factor: 5.923

7. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway.

Authors: Kaimin Hu; Yanjun Gu; Lixia Lou; Lizhen Liu; Yongxian Hu; Binsheng Wang; Yi Luo; Jimin Shi; Xiaohong Yu; He Huang
Journal: J Hematol Oncol Date: 2015-01-27 Impact factor: 17.388